NCT06889740View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

December 8, 2024

Study Completion Date

January 25, 2025

Conditions

Healthy Aging

Interventions

OTHER

NMNH

Reduced Nicotinamide Mononucleotide

OTHER

Placebo

Starch powder

Trial Locations (2)

560092

Medstar Speciality Hospital, Bengaluru

609609

Vinayaka Mission's Medical College and Hospital, Kāraikāl

All Listed Sponsors

lead

EffePharm LTD

INDUSTRY

NCT06889740 - Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants | Biotech Hunter | Biotech Hunter